Replies to post #191744 on Biotech Values

[biomaven0]

>>can’t be used for Praluent (PCSK9) since the Praluent BLA already obtained a priority review

Can't exactly argue with that observation. :)

Glancing over their late-stage portfolio, seems like their anti-IL6R RA drug or their GLP-1 diabetes drug would seem to be the plausible candidates.

Peter